Evidence map›Paper›PMID 24827702›Full record

ReviewPediatric diabetes2014

Autoimmune responses in T1DM: quantitative methods to understand onset, progression, and prevention of disease.

Majid Jaberi-Douraki, Shang Wan Shalon Liu, Massimo Pietropaolo, Anmar Khadra

Registry-linked trialAbstract readReview
In one paragraph

Review in Pediatric diabetes, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02929953 (Prevalence of Premature Birth History Among Type 1 Diabetes Mellitus), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02929953 completednot on this map

Prevalence of Premature Birth History Among Type 1 Diabetes Mellitus (T1D) Patients and Characteristics of Premature Born Children Who Develop T1D Compared With Those Who do Not

TypeobservationalSponsorAssaf Harofeh MCRan2014 to 2019Enrolled3,600ConditionsType 1 Diabetes MellitusArmschart review
3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Majid Jaberi-DourakiDepartment of Physiology, McGill University, Montreal, Quebec, Canada.
Shang Wan Shalon Liu
Massimo Pietropaolo
Anmar Khadra

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
IMPROVING PREDICTION OF IDDMR01DK053456 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HERMAN, MARK A, REDONDO, MARIA JOSE · 1999 to 2021
$9.5M
EPIDEMIOLOGY OF ISLET CELL AUTOIMMUNITY IN NIDDMR01DK056200 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PIETROPAOLO, MASSIMO T · 2001 to 2009
$3.5M
Proteomics of Autoimmune Type 1 DiabetesR21DK073724 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PIETROPAOLO, MASSIMO T · 2005 to 2006
$410k
NIDDK NIH HHS P30 DK020572NIDDK NIH HHS R01 DK053456NIDDK NIH HHS R01 DK056200NIDDK NIH HHS R01 DK53456NIDDK NIH HHS R01 DK56200NIDDK NIH HHS R21 DK073724
6 · The paper itself

Abstract

Understanding the physiological processes that underlie autoimmune disorders and identifying biomarkers to predict their onset are two pressing issues that need to be thoroughly sorted out by careful thought when analyzing these diseases. Type 1 diabetes (T1D) is a typical example of such diseases. It is mediated by autoreactive cytotoxic CD4⁺ and CD8⁺ T-cells that infiltrate the pancreatic islets of Langerhans and destroy insulin-secreting β-cells, leading to abnormal levels of glucose in affected individuals. The disease is also associated with a series of islet-specific autoantibodies that appear in high-risk subjects (HRS) several years prior to the onset of diabetes-related symptoms. It has been suggested that T1D is relapsing-remitting in nature and that islet-specific autoantibodies released by lymphocytic B-cells are detectable at different stages of the disease, depending on their binding affinity (the higher, the earlier they appear). The multifaceted nature of this disease and its intrinsic complexity make this disease very difficult to analyze experimentally as a whole. The use of quantitative methods, in the form of mathematical models and computational tools, to examine the disease has been a very powerful tool in providing predictions and insights about the underlying mechanism(s) regulating its onset and development. Furthermore, the models developed may have prognostic implications by aiding in the enrollment of HRS into trials for T1D prevention. In this review, we summarize recent advances made in determining T- and B-cell involvement in T1D using these quantitative approaches and delineate areas where mathematical modeling can make further contributions in unraveling certain aspect of this disease.

Indexed as

AutoimmunityCytotoxicity, ImmunologicModels, BiologicalAnimalsAutoantibodiesBiomarkersDiabetes Mellitus, Type 1Disease ProgressionHumansInsulinInsulin-Secreting CellsInsulin SecretionPrognosisAutoantibodiesBiomarkersInsulinislet cell antibodyautoantibodiesautoimmunityavidityB-cellsMarkov modelsmathematical modelspredictive algorithmsT1DT-cellsβ-cells

Identifiers

PMID24827702
PMCPMC4050373

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.